{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lung+Carcinoma", "query": { "condition": "Refractory Lung Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 259, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lung+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T09:21:08.648Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04993677", "title": "A Study of SEA-CD40 Given With Other Drugs in Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Carcinoma, Non-Small- Cell Lung" ], "interventions": [ { "name": "SEA-CD40", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2021-10-06", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2025-05-11", "last_synced_at": "2026-06-25T09:21:08.648Z", "location_count": 23, "location_summary": "Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04993677" }, { "nct_id": "NCT01495663", "title": "Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "I-131-CLR1404", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2011-12", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2015-02-26", "last_synced_at": "2026-06-25T09:21:08.648Z", "location_count": 3, "location_summary": "Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495663" }, { "nct_id": "NCT05130255", "title": "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SCLC", "Malignant Melanoma", "Sarcoma", "High Risk Neuroblastoma" ], "interventions": [ { "name": "GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (3 mg/kg) 177Lu-DOTA (200 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (30 mCi)", "type": "DRUG" }, { "name": "GD2-SADA (1 mg/kg) 177Lu-DOTA (100 mCi)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Y-mAbs Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 23, "start_date": "2022-11-17", "completion_date": "2026-03-11", "has_results": true, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-06-25T09:21:08.648Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Duarte, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130255" }, { "nct_id": "NCT03058289", "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "Lymphoma", "Pancreatic Cancer", "Liver Cancer", "Colon Cancer", "Lung Cancer", "Bile Duct Cancer", "Chordoma of Sacrum", "Sarcoma" ], "interventions": [ { "name": "INT230-6", "type": "DRUG" }, { "name": "anti-PD-1 antibody", "type": "BIOLOGICAL" }, { "name": "anti-CTLA-4 antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Intensity Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-02-09", "completion_date": "2023-02-22", "has_results": true, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-06-25T09:21:08.648Z", "location_count": 7, "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03058289" }, { "nct_id": "NCT01061788", "title": "A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors, Non-small Cell Lung Cancer" ], "interventions": [ { "name": "AMG 479, Everolimus, Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey Clarke", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 43, "start_date": "2010-04", "completion_date": "2018-12-19", "has_results": false, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-06-25T09:21:08.648Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01061788" }, { "nct_id": "NCT01391143", "title": "Safety Study of MGA271 in Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Melanoma", "Renal Cell Carcinoma", "Triple-negative Breast Cancer", "Head and Neck Cancer", "Bladder Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "MGA271", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 179, "start_date": "2011-07", "completion_date": "2019-04-18", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-06-25T09:21:08.648Z", "location_count": 12, "location_summary": "Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01391143" }, { "nct_id": "NCT02423343", "title": "A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non-Small Cell Lung Cancer Recurrent", "Hepatocellular Carcinoma Recurrent" ], "interventions": [ { "name": "Galunisertib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2015-01-01", "completion_date": "2020-07-08", "has_results": true, "last_update_posted_date": "2021-09-09", "last_synced_at": "2026-06-25T09:21:08.648Z", "location_count": 5, "location_summary": "Birmingham, Alabama • La Jolla, California • Tampa, Florida + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02423343" }, { "nct_id": "NCT00006347", "title": "Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "indium In 111 monoclonal antibody MN-14", "type": "RADIATION" }, { "name": "yttrium Y 90 monoclonal antibody MN-14", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Garden State Cancer Center at the Center for Molecular Medicine and Immunology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-03-03", "last_synced_at": "2026-06-25T09:21:08.648Z", "location_count": 1, "location_summary": "Belleville, New Jersey", "locations": [ { "city": "Belleville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006347" }, { "nct_id": "NCT02983578", "title": "Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Colorectal Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Lung Non-Small Cell Carcinoma", "Mismatch Repair Deficiency", "Refractory Colorectal Carcinoma", "Refractory Lung Carcinoma", "Refractory Pancreatic Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Danvatirsen", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-03-02", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-06-25T09:21:08.648Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983578" }, { "nct_id": "NCT03224871", "title": "UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "METASTATIC NON-SMALL CELL LUNG CANCER" ], "interventions": [ { "name": "Intralesional IL-2", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-08-11", "completion_date": "2020-01-10", "has_results": false, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-06-25T09:21:08.648Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03224871" } ] }